506 related articles for article (PubMed ID: 15947583)
1. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
Nieuwenhuijzen JA; Bex A; Meinhardt W; Kerst JM; Schornagel JH; VAN Tinteren H; Horenblas S
J Urol; 2005 Jul; 174(1):80-5. PubMed ID: 15947583
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
[TBL] [Abstract][Full Text] [Related]
3. Can patient selection for bladder preservation be based on response to chemotherapy?
Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
[TBL] [Abstract][Full Text] [Related]
4. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
5. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
Kuroda M; Kotake T
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():362-9. PubMed ID: 7986116
[TBL] [Abstract][Full Text] [Related]
6. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
Lehmann J; Franzaring L; Thüroff J; Wellek S; Stöckle M
BJU Int; 2006 Jan; 97(1):42-7. PubMed ID: 16336326
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
8. [Prognosis in pT3b infiltrating tumors of the bladder treated by adjuvant chemotherapy].
Sahwi A; Robert M; Delbos O; Legouffe E; Guiter J; Navratil H
Prog Urol; 1998 Dec; 8(6):1007-11. PubMed ID: 9894259
[TBL] [Abstract][Full Text] [Related]
9. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: preliminary report of a non-randomized study.
Galante E; Ferroni C; Bianchi S; Megale C; Molinaro S; Maymone S
J Exp Ther Oncol; 1996 Jul; 1(4):237-41. PubMed ID: 9414410
[TBL] [Abstract][Full Text] [Related]
12. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
[TBL] [Abstract][Full Text] [Related]
13. [Is neoadjuvant chemotherapy valid in invasive cancer of the bladder?].
Matveev BP; Figurin KM
Urol Nefrol (Mosk); 1998; (6):42-5. PubMed ID: 10051828
[TBL] [Abstract][Full Text] [Related]
14. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Qureshi KN; Griffiths TR; Robinson MC; Marsh C; Roberts JT; Hall RR; Lunec J; Neal DE
Clin Cancer Res; 1999 Nov; 5(11):3500-7. PubMed ID: 10589764
[TBL] [Abstract][Full Text] [Related]
15. Surgical factors influence bladder cancer outcomes: a cooperative group report.
Herr HW; Faulkner JR; Grossman HB; Natale RB; deVere White R; Sarosdy MF; Crawford ED
J Clin Oncol; 2004 Jul; 22(14):2781-9. PubMed ID: 15199091
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-based neoadjuvant chemotherapy for invasive bladder cancer.
Kadena H; Igawa M; Shigeta M; Nakamoto T; Usui T
Hiroshima J Med Sci; 1995 Dec; 44(4):129-32. PubMed ID: 8857236
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy.
Park J; Park S; Song C; Doo C; Cho YM; Ahn H; Kim CS
Urology; 2007 Aug; 70(2):257-62. PubMed ID: 17826485
[TBL] [Abstract][Full Text] [Related]
19. [M-VAC chemotherapy for patients with lymph node metastases and/or locally advanced bladder carcinoma].
Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Nakatsu H; Kume T; Kodama M; Masu C
Hinyokika Kiyo; 1989 Aug; 35(8):1323-7. PubMed ID: 2683648
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of bulky stage IB and IA cervical cancer patients treated by radical hysterectomy with and without neoadjuvant chemotherapy: long-term follow-up.
Manusirivithaya S; Chareoniam V; Pantusart A; Isariyodom P; Srisomboon J
J Med Assoc Thai; 2001 Nov; 84(11):1550-7. PubMed ID: 11853297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
